Interesting snip from article in the PharmaLive newsletter-
thanks to Cheryl-Anne for the link.
Sandy
"Tasigna: "Path to Cure" - a potential paradigm shift in CML treatment.
Novartis has transformed Ph+ chronic myeloid leukemia (CML) to a treatable, chronic condition and is again on the way to redefine what is possible in CML. The new goal is for patients to live free of drug therapy once they have achieved long-term response to treatment. Tasigna, a potent 2nd generation targeted therapy for CML, has demonstrated a reduced risk of progression and deeper and more sustained molecular response than Glivec.
Based on these advances, as well as advances in molecular response monitoring, in 2013 the company plans to initiate Tasigna clinical trials to explore the goal of achieving sustained treatment-free remission in patients living with CML.
If positive, this could lead to a major paradigm shift in CML treatment."
http://pharmalive.com/news/index.cfm?articleID=865843&categoryid=9&newsl...